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1. RESUME 
 
 
Les maladies cardio-vasculaires représentent la cause la plus importante de 
mortalité et de morbidité dans les pays occidentaux. La thérapie génique offre une 
nouvelle approche au traitement de ces maladies. L’expression de gènes 
protecteurs dans le myocarde par des technologies de transfert génique peut 
améliorer la fonction ventriculaire lors de l’insuffisance cardiaque ou stimuler la 
formation de nouveaux vaisseaux dans la maladie coronarienne. Etant donné 
qu’une majorité des maladies cardiaques sont des maladies chroniques, 
l’expression durable du gène thérapeutique introduit dans le cœur est souhaitable 
dans de nombreux cas. Malheureusement, l’utilité des vecteurs de transfert génique 
les plus utilisés en thérapie génique cardiovasculaire est limitée par une 
performance faible (ADN plasmidique) et une courte durée d’expression 
(adénovirus). Récemment, des vecteurs de transfert génique dérivés des lentivirus, 
une sous-famille des rétrovirus, ont retenu l’attention de la communauté scientifique 
en raison de leur capacité à exprimer des gènes à long terme. Contrairement aux 
vecteurs rétroviraux traditionnels, les vecteurs lentiviraux transduisent des gènes 
même dans des cellules qui ne se divisent pas, ce qui est le cas des 
cardiomyocytes adultes. Ces vecteurs présentent un profil de biosécurité 
comparable à celui des vecteurs rétroviraux traditionnels. Nous avons donc décidé 
de tester l’utilité des vecteurs lentiviraux pour le transfert génique dans des 
cardiomyocytes de rat adulte in vitro et in vivo. 
Plusieurs versions de vecteurs lentiviraux contenant différent promoteurs ont été 
construites. Ces vecteurs contenant le gène marqueur EGFP (enhanced green 
fluorescent protein) ont été testés dans des cardiomyocytes de rat in vitro, ainsi que 
dans des cœurs de rat in vivo. Le but de ces expériences était de déterminer la 
durée de l’expression du transgène après injection intramyocardique chez le rat. 
Pour ce faire, nous avons développé une technique ELISA pour détecter la protéine 
EGFP dans des extraits de tissu cardiaque. Les résultats ont montré que la protéine 
EGFP était encore présente à des niveaux significatifs jusqu’à dix semaines après 
l’injection de vecteurs lentiviraux, alors que l’expression transgénique obtenue avec 
un vecteur adénoviral traditionnel a été plus limitée dans le temps. Ces résultats 
démontrent la capacité des vecteurs lentiviraux à exprimer des gènes d’intérêt de 
manière performante et stable dans le cœur de rat adulte in vivo. 
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2. SUMMARY 
 
Cardiovascular diseases are the first cause of morbidity and mortality in 
Western countries. Gene therapy offers a new approach to these diseases. 
Expression of therapeutic genes in the myocardium by gene transfer technologies 
can improve ventricular function in heart failure and stimulate neovascularization in 
coronary disease. 
 
Chronic heart diseases likely require sustained expression of the therapeutic 
gene within the heart itself. Unfortunately, the most commonly used vectors in 
cardiovascular gene therapy, i.e. plasmid DNA and recombinant adenovirus 
vectors, are limited by poor DNA uptake and  transient transgene expression, 
respectively. Recently, lentivirus-derived vectors have attracted much interest 
because of their ability to achieve long-term transgene expression. In contrast to 
traditional retroviral vectors, lentiviral vectors are also able to transduce non-
dividing cells, while presenting a comparable biosafety profile. Adult 
cardiomyocytes are terminally differentiated cells that do not divide under normal 
conditions. For these reasons, we have decided to evaluate the efficiency of 
lentiviral vectors for gene-transduction of adult cardiomyocytes both in vitro and in 
vivo. 
 
We constructed various types of lentiviral vectors containing various 
promoters. Vectors encoding EGFP as a reporter gene were tested in rat 
cardiomyocytes in vitro and in rat hearts in vivo. The aim of the experiments 
involved in this thesis work was to determine the duration of the expression of the 
transgene after rat intramyocardial injection using a quantitative assay. Therefore, 
an ELISA technique was set up to measure the EGFP protein in rat heart tissue 
extracts. Our results showed that the EGFP protein was still present at significant 
levels at ten weeks after lentiviral vector injection, whereas the duration of 
expression with adenoviral vectors was shorter. These results demonstrate that 
lentiviral vectors efficiently deliver genes and achieve sustained transgene 
expression in adult rat cardiomyocytes in vivo. 
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3. INTRODUCTION 
 
 
Cardiovascular diseases are the leading cause of morbidity and mortality in 
Western countries. The pathogenesis of these diseases is complex and involves 
both genetic and environmental factors. An increasing number of genes that are 
responsible for inherited heart diseases, including familial cardiomyopathies and 
familial arrhythmias have been identified in recent years [1]. Major advances in 
human genetics, in cell biology and in virology have resulted in the emergence of 
gene therapy, which is defined as the genetic modification of somatic cells of an 
individual in order to produce a therapeutic effect. Gene therapy is a very 
promising approach to the treatment of cardiovascular diseases. The vast majority 
of heart gene therapy studies have focused on acquired heart diseases such as 
ischaemic heart disease and heart failure [2]. A dozen of clinical phase I/II trials 
are currently being carried out in patients with severe coronary artery disease 
worldwide [3, 4]. These trials involve the delivery of angiogenic genes to ischaemic 
hearts in an attempt to stimulate the formation of new coronary vessels. 
 
Efficient gene transfer of a therapeutic factor requires an appropriate vector to 
deliver the DNA to the host tissues [5]. Nowadays, available vehicles for somatic 
gene transfer can be divided into two general categories: non-viral and viral 
vectors [6]. Naked plasmid DNA, antisense oligonucleotides, liposome-DNA 
complexes and cationic polymer-DNA complexes belong to the first category. The 
more noticeable weakness of non-viral vectors is the relatively poor DNA uptake, 
even though major advances have recently been scored with liposome vectors. 
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Among viral vectors, adenovirus-derived vectors are the most commonly used 
vectors in cardiovascular gene therapy. Although adenoviral vectors achieve 
substantially higher gene-transduction efficiencies than plasmid DNA vectors, 
transgene expression is typically transient, probably due to strong tissue 
inflammation induced by viral proteins [7]. In contrast, retroviral vectors are believed 
to be less immunogenic than adenoviral vectors and are able to integrate the 
transgene into the genome of target cells, thus providing a potential for permanent 
genetic manipulations of target tissues [8,9]. However, conventional retroviral vectors 
derived from oncoretroviruses, such as the Moloney-murine leukemia virus (MLV), 
require the breakdown of the nuclear envelope during mitosis for the nuclear 
translocation of the pre-integration complex. Consequently, MLV vectors are of 
limited usefulness in nondividing cells, including cardiomyocytes. 
 
Among Retroviridae, the genus Lentiviridae, including human immunodeficiency virus 
type 1 (HIV-1), is unique in that it is independent of cell division for completion of the 
replication cycle [10]. The pre-integration complex of HIV-1 contains nuclear 
localization signals that mediate transport through the nucleopore during interphase 
[11]. HIV-1-based vectors have been effective in delivering genes to several tissues 
including the brain, the liver, skeletal muscle and retina in vivo [12,13,14]. However, 
their efficiency has not been equal in all of the tissues. Post–entry restriction to 
lentiviral gene transduction has been reported in human haematopoietic stem cells 
and monocytes in vitro, as well as in liver cells in vivo [15,16,17]. Cell type-specific 
requirements have been identified for efficient lentiviral gene transduction, which 
involve cell activation and cell cycle progression, but not necessarily mitosis. 
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Because mammalian cardiomyocytes lose their ability to proliferate and exit the cell 
cycle soon after birth [18], retroviral vectors are inefficient at transducing genes into 
adult cardiomyocytes. Although mitosis in human cardiomyocytes has been 
demonstrated after myocardial infarction [19], this process is thought to involve a 
small percentage of cells and, hence, it cannot be taken advantage of for gene 
transfer with MLV vectors. Therefore, HIV-1–based vectors are attracting increasing 
interest for myocardial gene transfer. However, biosafety issues with these vectors 
have not been entirely solved. In fact, the configuration of early-generation HIV-1 
vectors was still too similar to their dreadful parent (Fig. 1). Recently, this problem 
was partially solved by using multiply attenuated (i.e., with large deletions of the HIV 
genome), self-inactivating HIV-1-based vectors (Fig. 2) [20,21]. 
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structure of wild-
type HIV-1. 
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Although lentiviral gene transduction into fetal human cardiomyocytes and neonatal 
rat cardiomyocytes in vitro has been reported previously [22,23], efficient gene 
transduction into adult cardiomyocytes in vivo has not been reported. Because of 
several differences between cell cycle regulation and metabolic activation between 
neonatal and adult cardiomyocytes, previous data in neonatal rat and mouse 
cardiomyocytes, which maintain a proliferative activity, cannot be extrapolated to 
adult cardiomyocytes. Preliminary work done in the Laboratory of Molecular 
Cardiology at the CHUV has demonstrated that lentiviral vectors optimized with 
respect to internal promoters and cis-acting sequences efficiently transduce genes 
into adult cardiomyocytes in vitro. Thus, the present project has involved testing of 
the improved lentiviral vectors in adult rat myocardium in vivo. 
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4. METHODS 
 
 
Transfer vector constructs. 
SIN vectors were produced from the previously described SIN-18 vector, which 
contains a large deletion in the U3 region of the 3’ long terminal repeat (LTR; Fig. 
3) [20]. The SIN.CMV-EGFP-W vector contains the enhanced green fluorescent 
protein (EGFP) gene under the transcriptional control of the human 
cytomegalovirus immediate-early enhancer/promoter (CMVie). In the SIN.PGK-
EGFP-W and SIN.EF1α-EGFP-W vectors, EGFP expression is driven by the 
murine phosphoglycerate kinase (PGK) promoter (nucleotides 424 to 930) [21] 
and the human elongation factor-1α (EF1α) promoter (nucleotides 373 to 1561) 
[24], respectively. The post-transcriptional regulatory element of woodchuck (W) 
hepatitis virus was inserted between the EGFP gene and the 3’LTR as described 
[25]. A 118-bp sequence from HIV-1 pol encompassing the central polypurine tract 
(cPPT) and termination sequences was subcloned upstream of the internal 
promoter to generate the SIN.cPPT.CMV-EGFP-W, SIN.cPPT.PGK-EGFP-W, and 
SIN.cPPT.EF1α-EGFP-W vectors [26]. 
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Packaging constructs. 
pMDLg/pRRE is a CMV-driven expression plasmid that encodes the viral capsid. It 
contains the gag, pol coding sequences and a 374-bp Rev-responsive element 
(RRE)-containing sequence from HIV-1 downstream of the pol coding sequences 
(Fig. 4) [21]. pCMVDR-8.92 is another capsid encoding plasmid derived from 
pCMVDR-8.91, which contains the tat coding sequence and a destruction of the 
BamHI restriction site in the coding region of rev [21]. RSV-Rev is a rev expressing 
plasmid in which the joined second and third exons of HIV-1 rev are under the 
control of the Rous sarcoma virus U3 promoter [21]. pMD2.G is a CMV-driven 
expression plasmid that encodes the vesicular stomatitis virus (VSV)-G envelope 
protein. Plasmids were purified with endotoxin-free kits (Qiagen). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Packaging system (part 2) 
pRSV-REV 
Packaging system (part 1) 
pMDLg/pRRE 
  polyARSV-U3 REV
POL 
SA  SD
G  AG
PRO 
polyARRE CMV 
promoter 
Envelope construct 
pMD2.VSV-G 
VSV-G polyA
CMV
promoter 
SA SD 
Fig. 4: Packaging and 
envelope plasmids used for 
co-transfection with the 
vector plasmid for lentiviral 
vector production in 293T 
cells. 
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Lentiviral vectors. 
Pseudotyped, HIV-1-based vector particles were produced by co-transfection of 
four plasmids (pMDLg/pRRE: 12 µg; pRSVrev: 3 µg; pMD2.G: 5 µg, SIN vector: 
20µg) onto 293T cells as described [20]. Lentiviral vector preparations were made 
with the tat–deleted pMDLg/pRRE plasmid, with the exception of a single 
SIN.cPPT.CMV-EGFP-W preparation made with the tat–containing pCMVDR-8.92 
plasmid. Culture medium was replaced by serum-free SFM-II medium (Invitrogen) 
15 hrs post-transfection. Thirty-two hours later, cell supernatants were harvested, 
filtered through a 0.45 µm filtration system, concentrated on Centricon Plus-80 
Biomax-MW 100'000 (Millipore), resuspended in PBS, and concentrated on 
Centricon-20. Virus titers were determined by flow cytometry (FACSCalibur) on 
293T cells 72 hrs post-infection, as well as using a p24 ELISA. Titers of virus 
preparations made in the absence of Tat were 4-6x108 transducing units (TU)/ml, 
or 3-3.5x104 ng p24/ml. Virus titer of the SIN.cPPT.CMV-EGFP-W preparation 
made in the presence of Tat was 5x109 TU/ml, or 5x104 ng p24/ml. 
 
Adenoviral vectors. 
An E1/E3-deleted adenoviral vector (Ad.CMV-EGFP) containing the CMVie-driven 
EGFP gene was prepared as described [27]. Virus titers were 2.5x1011 plaque 
forming units/ml by plaque assay on 293 cells, and 3.0x1011 TU/ml by FACS on 
293T cells 20 hours post-infection. 
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In vivo gene transfer into rat myocardium. 
All animal procedures were approved by the Veterinary Office of Canton de Vaud. 
Male Wistar rats (12-16 week-old; purchased from Iffa-Credo, L’Arbresle, France) 
were anesthetized with intraperitoneal ketamine (66.7 mg/kg; Parke-Davis) and 
xylazine (6.7 mg/kg; Bayer), intubated, and mechanically ventilated. A 
thoracotomy was performed in the 5th left intercostal space, and viral vectors were 
injected (20 µl of vector containing solution) with a 32-gauge needle into the left 
ventricular apex. For histological analysis, a first series of rats received 
SIN.cPPT.CMV-EGFP-W (n=9), SIN.cPPT.EF1α-EGFP-W (n=7), and 
SIN.cPPT.CMV-LacZ-W (n=3) lentiviral vectors (107 to 108 TU), adenovirus 
Ad.CMV-EGFP stock solution (108 TU; n = 3), or PBS alone (n=5). For studying 
gene expression kinetics, lentivectors were prepared with tat containing packaging 
plasmids to achieve higher vector titers, and rats received lentivectors diluted in 
PBS (5x107 TU) of SIN.cPPT.CMV-EGFP-W (n=20), SIN.cPPT.EF1α-EGFP-W 
(n=14), 1:100-diluted Ad.CMV-EGFP vector stock solution (6x107 TU; n = 8), or 
PBS alone (n=3; controls). At varying time intervals (1-10 weeks) after gene 
transfer, rats were sacrificed by lethal pentobarbital injection and hearts used for 
histology were perfusion-fixed with PBS 4%-paraformaldehyde. Hearts used for 
EGFP protein quantification by ELISA or immunohistochemistry for assessing 
tissue inflammation were perfused with PBS only. 
 
Histological and immunohistochemical analysis. 
Histology and immunohistochemistry were performed on cryostat sections (hearts 
were frozen at -80oC in OCT-compound). For histology, two series of 8-µm 
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sections (n = 40 each) per heart were cut at 200-µm steps from the apex to the 
base. The first series was used for EGFP detection by direct fluorescence 
microscopy and the second series was stained with hematoxylin and eosin. 
Immunohistochemical analysis of infiltrating leukocytes was performed at day 6 
post-injection on cryostat sections. Detection of cell sub-populations was 
performed by incubating cardiac sections overnight at 40C with the following mAbs: 
irrelevant mouse mAb MOPC-31C as negative control, 1C7 anti-
monocytes/macrophages (ED-1-like), anti-αβ TCR (R73), and anti CD8α (OX-8), 
which are all from PharMingen (BD Biosciences, Europe), while anti-CD4 (W3/25) 
is from Accurate Chemicals (USA). Slides were then incubated with a biotin-
conjugated rabbit F(ab’)2 anti-mouse Ig for 45 minutes (Jackson ImmunoResearch 
Laboratorie, Inc., USA), followed by StreptABComplex/HRP for 20 minutes and 
DAB/H2O2 as substrate (Dako, Europe). For immunofluorescence, sections were 
incubated with a secondary goat F(ab’)2 anti-mouse FITC-labelled antibody for 1 
hour (Jackson ImmunoResearch Laboratories, Inc., USA).  
 
Morphometric analysis of tissue inflammation after injection of lentiviral or 
adenoviral vectors into adult rat hearts in vivo.  
Cardiac cross section areas staining positive with the above mAb’s were 
measured with the NIH-Image-1.62 morphometry program and expressed as 
percentage of total myocardial areas. 
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Detection of the reporter gene protein Enhanced Green Fluorescent Protein 
(EGFP) by Enzyme Linked Immunoadsorbent Assay (ELISA). 
The apex of the heart injected with EGFP expressing vectors or PBS was cut off, 
weighted, and the tissue was dispersed into individual cells with a Potter 
homogenizer of 2 ml. Total cytoplasmic proteins were then extracted with the NE-
PER™ kit (Pierce, USA). EGFP proteins contained in the different lysates were 
quantified by a modified ELISA protocol (Fig. 5) using the React-bind™ anti-GFP 
coated clear strip plates. Briefly, 100 µl of sample diluted 1/2 and 1/75 (triplicate) 
with the Assay Diluent for OptEIA™ (PharMingen) were coated for 1 hour at room 
temperature. Plates were then washed and rabbit anti-GFP serum was added for 1 
hour (IgG fraction from Molecular Probes, Europe), followed by a goat anti-rabbit 
biotinylated antibody for 1 hour. Streptavidin-HRP was then added for 45 minutes 
before adding the TBM substrate. The reaction was stopped by adding 100 µl of 
H2SO4 1.8 N and plate-reading was done at 450 nm by spectrophotometry for 
ELISA plates. The recombinant EGFP protein (Molecular Probes, Europe) was 
used for making a 4-fold dilution standard curve (0.9 to 4,000 pg/mL). 
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Fig. 5: Scheme of the ELISA test used for measuring EGFP levels in rat 
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5. RESULTS 
 
Lentiviral vectors achieve sustained transgene expression in vivo. 
EGFP-positive cardiomyocytes were detected by direct fluorescence 
microscopy on heart sections up to 10 weeks after lentiviral gene transfer (Fig. 6). 
However, histology does not allow to quantify the overall amount of transgene 
product expressed in the tissue and, hence, to precisely assess stability of transgene 
expression. For this reason, we developed an ELISA to quantify the total amount of 
EGFP present in cytoplasmic proteins extracted from injected hearts. A typical ELISA 
standard curve obtained with purified recombinant EGFP is shown in figure 7. The 
EGFP content in cardiac samples was expressed as picograms of EGFP normalized 
per gram of heart tissue. 
EGFP content in tissue extracts from hearts of rats sacrificed at varying time 
points after gene transfer with lentivectors and adenovectors is shown in figure 8. 
Using the CMV-EGFP construct expressed from the lentivector, the EGFP was 
detectable as early as 3 days post-injection (5,200 pg), peaked at 7 days (35,230 pg) 
followed by a rapid decline of ~7-fold at 14 days (5,125 pg). Afterwards, a slower 
decrease of the EGFP was observed, which corresponds to a ~2-fold decrease 
between week 2 (median 5,125 pg) and week 4 (2,427 pg), and a ~2.5-fold decrease 
between week 4 and week 10 (1,000 pg). Using EF-1α promoter-containing 
lentivectors, EGFP expression at day 7 (42,828 pg) was slightly higher than with the 
CMV promoter. However, EGFP expression from the EF1α promoter strongly 
decreased by >3000-fold at 4 weeks (137 pg), as compared to a 15-fold decrease 
with the CMV promoter. At week 10, EGFP from the EF1α promoter was barely 
detectable (60 pg), which is 16-fold lower than with the CMV promoter (1,000 pg). 
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Longitudinal view of 
EGFP expressing 
cardiomyocytes 
Transversal view of 
EGFP expressing 
cardiomyocytes 
Fig. 6: Direct fluorescence photomicrographs showing EGFP expression in cardiomyocytes 
6 days after lentiviral vector injection into adult rat hearts in vivo. 
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In contrast, adenovirus-mediated EGFP expression peaked earlier than 
lentiviral expression, i.e. at 3 days (44,000 pg), decreased by two-fold at 14 days  
(27,813 pg), and was barely detectable at 10 weeks (79 pg). Surprisingly, these 
results indicate that EGFP expression with EF1α promoter containing lentivectors or 
CMV promoter-containing adenovectors is poorly maintained on a long-term basis in 
vivo, while EGFP expression using CMV promoter containing lentivectors is 
sustained for up to 10 weeks after vector injection. 
 
 
 
 Standard curve of EGFP ELISA  
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Fig. 7: standard curve used for the quantification of the EGFP transgene expression 
in adult rat myocardium in vivo. The standard curve was made with serial dilutions of 
recombinant EGFP to define the sensitivity of the assay. 
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Fig. 8: EGFP ELISA of transgene expression in adult rat cardiomyocytes in vivo. Rat hearts 
were cut and total cytoplasmic proteins extracted at 3 days, as well as at 2, 4 and 10 
weeks post-injection of lentiviral vectors contianing CMV or EF1α promoters.  
 
Tissue inflammation reflects vector diffusion through the myocardium. 
Tissue integrity and inflammatory cell infiltrates were evaluated on 
immunohistochemically stained sections at 12 days after intramyocardial injection of 
SIN.cPPT.CMV-EGFP-W, Ad.CMV-EGFP, or PBS and by computer morphometric 
analysis (Fig. 9). Microscopic analysis revealed that hearts injected with adenoviral 
vectors showed more severe damage than those injected with lentiviral vectors, as 
shown by differences in tissue structure integrity (Fig 10-11-12-13). Furthermore, 
when inflammatory cells infiltrates were monitored by immunohistochemistry, we 
observed that lentiviral vectors cause inflammation that is generally restricted to the 
site of injection into the apex, where EGFP expression is also observed (Fig 10-11-
12-13). In contrast, adenovirus-injected hearts showed inflammatory cells that were 
more widely distributed throughout the neighbouring regions, which also 
corresponded to a larger distribution of EGFP expression.  
With both adenovectors and lentivectors, the most abundant cell population 
within inflammatory cell infiltrates was monocytes/macrophages (1C7 mAb 
recognizes ED1-like), as detected by the anti-CD4 (W3/25) mAb. The second most 
abundant population within inflammatory infiltrates was CD8+ T cells, as detected by 
R73 mAb anti-αβ TCR and OX-8 mAb anti-CD8α (Fig. 12-13). Rare B cells (OX-33 
mAb) were also present (not shown). The fact that EGFP-positive cells within 
lentivector-injected hearts were localized mostly in close proximity to the injection site 
may suggest a poor diffusion of lentiviral vectors across myocardial layers, which 
could explain the restricted area of tissue inflammation observed after lentivector 
injection, as compared to more diffuse inflammation observed with adenovectors. 
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Fig. 9: Morphometric analysis of tissue inflammation after injection of lentiviral or adenoviral 
vectors into adult rat hearts in vivo. Cardiac cross section areas staining positive with the 
above mAb’s were measured with the NIH morphometry program and expressed as 
percentage of total myocardial areas. Lentivectors induced less inflammation than 
adenovectors in peripheral areas. MIS = mean positive surface (%). 
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A) PBS control 
 
 
B) lentiviral vector injection site 
 
 
C) lentiviral vector distal to 
injection site 
 
D) adenoviral vector injection site 
 
 
E) adenoviral vector distal to 
injection site 
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Fig 10: Immunohistochemical analysis of virally gene-transduced hearts. 1C7 mAb 
recognizes ED1-like antigen on monocytes and macrophages. The secondary antibody was 
coupled with biotin, which was revealed by streptavidin HRP.  
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Fig. 11: immunohistochemistry. W3/25 mAb recognizes CD4 on macrophages and CD4+ T  
lymphocytes. The secondary antibody was coupled with biotin, which was revealed by streptavidin HRP. 
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Fig. 12: Immunohistochemical analysis of virally gene-transduced hearts. The primary 
antibody OX-8 mAb recognizes CD8α on CD8+T lymphocytes. The secondary antibody 
was coupled with biotin, which was revealed by streptavidin HRP.  
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Fig. 13: immunohistochemical analysis of virally gene-transduced hearts. The primary 
antibody R73 mAb recognizes TCRαβ on CD8+ T lymphocytes. The secondary antibody was 
coupled with biotin, which was revealed by streptavidin HRP. 
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6. DISCUSSION. 
 
Lentiviral vectors efficiently transduce genes into rat myocardium in vivo. 
  
  The principal aims of this study were to quantify the efficiency of myocardial 
gene transfer with lentiviral vectors, as compared to adenoviral vectors, and to 
determine the duration of transgene expression with these vectors in rat 
cardiomyocytes in vivo. Previous reports have shown that lentiviral vectors are 
able to transduce genes into several cell types such as hepatocytes, skeletal 
muscle cells, haematopoietic stem cells, retinal cells and neurons. However, 
lentiviral in vivo gene transfer into adult cardiomyocytes has not been reported 
previously. 
 
 Histological analysis of transduced hearts (Fig. 6) demonstrated high-level 
EGFP expression that was clearly evidenced as a bright green signal by direct 
fluorescence microscopy. EGFP expressing myocytes were detected histologically 
up to 10 weeks after gene transfer with lentiviral vectors, but not with adenoviral. 
Compared to conventional adenoviral vectors containing a CMV-EGFP expression 
cassette, lentivectors containing either CMV or EF1α-driven EGFP cassettes 
achieved similar peak EGFP levels (EF1α-EGFP lentivirus : 42'828 pg; CMV-
EGFP lentivirus : 35'230 pg vs. CMV-EGFP adenovirus : 44'000 pg; NS). These 
results demonstrate efficient myocardial gene transduction with lentiviral vectors, 
at a level comparable with that observed with highly efficient adenoviral vectors. 
 
 
 
 24
 Lentiviral vectors achieve rapid myocardial transgene expression in vivo. 
 
  Adenoviral vectors are known to achieve rapid transgene expression, which is 
already detectable 8-12 hours after gene transfer. Consistently, we found that 
EGFP expression peaked at day 3 after adenoviral gene transfer, due to 
accumulation of the transgene product, but then rapidly declined by day 7 and 14. 
Lentivirus-mediated transgene expression was detectable at day 3 and peaked at 
day 7 using a CMV transgene promoter. The moderate delay in transgene 
expression with lentiviral as compared to adenoviral vectors is due to intracellular 
events required for lentiviral, but not for adenoviral, gene transfer including reverse 
transcription, second strand DNA formation, nuclear transport (which may be less 
effective than with adenoviral vectors), and chromosomal integration of the 
lentiviral genome. Nevertheless, it is remarkable that lentiviral vectors achieve 
significant transgene expression by day 3. This feature is important for gene 
therapy applications, as rapid transgene expression is likely required to treat acute 
and subacute disease conditions. In this regard, lentiviral vectors are more 
suitable than adeno-associated virus (AVV)-derived vectors, which are associated 
with a time lag in onset of expression by 1-2 weeks, due to second strand DNA 
synthesis and intracellular vector concatamer formation. 
 
Lentiviral vectors achieve prolonged myocardial transgene expression in 
vivo. 
 
  To quantitatively evaluate the time course of transgene expression after gene 
transfer with the two vectors, we developed an ELISA to detect EGFP contents in 
cardiac extracts at 3 days and at 1, 2, 4 and 10 weeks after gene delivery. 
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Consistently with the histological analysis of EGFP expression by direct 
fluorescence microscopy, this analysis showed that lentiviral, but not adenoviral, 
transgene expression lasted for 10 weeks (the latest time point studied) after gene 
transfer. However, the stability of EGFP expression was markedly different using 
CMV and EF1α promoter-containing vectors. Surprisingly, the CMV promoter, 
which is known to be frequently associated with transcriptional silencing of the 
transgene by cytokines in vivo, achieved more stable EGFP expression than the 
EF1α promoter, which is supposed to be less susceptile to transcriptional 
silencing. These data emphasize the importance of using multiple promoters to 
assess the stability of expression with a new candidate vector. 
 
 Although the CMV promoter achieved more stable EGFP expression than the 
EF1α promoter within lentiviral vectors, EGFP levels nevertheless decreased by 
almost one order of magnitude between day 7 and 14, while remaining relatively 
stable thereafter. The reason for the early decrease in EGFP expression is 
unclear, but cell damage in the context of inflammatory responses to needle injury 
or viral vectors is likely involved. An alternative, but not mutually exclusive, 
explanation would be that virus concentration was too high at the injection site, 
inducing cellular toxicity and/or antigen-specific immune responses against viral 
components or other components of the culture medium that co-purifiy with the 
virus during vector production. 
 
Tissue inflammation is stronger with adenoviral than with lentiviral vectors.  
 
  An additional purpose of this study was to determine which inflammatory cells 
subpopulations are present in order to caracterize the inflammatory process due to 
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the injection of lentiviral and adenoviral vectors. It was postulated that adenoviral 
vector may be more immunogenic than lentivectors due to residual expression of 
adenoviral genes from these vectors. Indeed, immunohistochemically stained 
sections of adult rat hearts injected either with SIN.cPPT.CMV-EGFP-W or with 
Ad.CMV-EGFP showed that adenovectors induce more damage to the tissue 
structure integrity both at the injection site and distally to it. The most abundant 
population in rat hearts was the macrophage/monocytes infiltrate which, to a 
lesser extent, was also observed in PBS injected hearts, suggesting that, at least 
in part, it was due to antigen-independant inflammatory responses to non-specific 
myocardial damage. The CD8 staining showed cell infiltration with CD8+ T 
lymphocytes, which were rare in PBS-injected hearts, suggesting the existence of 
an antigen-specific cytotoxic immune response to viral vectors or to other 
components of the culture medium. This leucocyte population was found in larger 
amounts in adenovirus-injected hearts, especially distal to the injection site, 
consistently with the observation that adenovirus-derived vectors diffuse more 
easily across the myocardium in vivo, as compared to lentiviral vectors, as 
indicated by the EGFP expression pattern. 
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7. CONCLUSIONS. 
 
 The results of these experiments demonstrate that lentiviral vectors achieve 
similar peaks of transgene expression than adenoviral vectors in adult rat hearts in 
vivo.  However, the time course of transgene expression was markedly different 
for the two vectors. Lentiviral vectors achieved significant transgene expression for 
10 weeks, at least, whereas adenoviral transgene expression declined rapidly over 
2 weeks. The kinetics of gene transfer with lentiviral vectors was only moderately 
slower than using adenoviral vectors. Transgene expression with lentiviral vectors 
was more stable using the CMV than the EF-1α promoter. 
 
 Despite the fact that lentivectors have a potential for stable transgene 
expression, due to the fact that the transgene is integrated in the host cell 
genome, an early loss of expression was also observed with lentiviral vectors. This 
was presumably due to tissue inflammation induced by the vector injection itself 
and, possibly, by immunogenic peptides contained in the virus solution. 
 
 These findings establish lentiviral vectors as a potentially useful gene delivery 
system for gene transfer-based approaches to chronic heart diseases. 
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